Nov 08, 2023 4:05pm EST Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
Nov 07, 2023 7:30am EST Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
Nov 01, 2023 7:00am EDT Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
Oct 11, 2023 7:30am EDT Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
Sep 22, 2023 5:25pm EDT Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
Sep 06, 2023 7:00am EDT Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
Aug 22, 2023 7:30am EDT Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
Aug 09, 2023 4:05pm EDT Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
